156 results about "Immunologic Reactions" patented technology

Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity.

The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.

Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.

The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants, as well as methods for making proteins less allergenic. In addition, the present invention provides various compositions that comprise these proteins that are less immunogenic than the wild-type proteins.

Provided herein are compositions comprising anti-HLA-Ib antibodies as IVIg mimetics and methods for using the same for the prevention, treatment, therapy and/or amelioration of inflammation induced diseases and allograft rejection. In certain embodiments, the anti-HLA-Ib antibodies (monoclonal antibodies or mixed monoclonal antibodies, recombinant or chimeric or humanized or human antibodies) strongly mimic IVIg in immunoreactivity to HLA class Ia (HLA-A, HLA-B and HLA-Cw) and Ib antigens (HLA-E, HLA-F and HLA-G). In certain embodiments, the anti-HLA-Ib antibodies (monoclonal or mixed monoclonal antibodies; recombinant, chimeric, humanized or human antibodies) strongly mimic IVIg in immunomodulatory or immunosuppressive activities. While anti-HLA-Ib mAbs can be used to restore anti-tumor activities of CD8+ T cells and Natural killer cells by passive therapy in cancer patients, methods are also provided herein to induce production of polyclonal anti-HLA-Ib antibodies in cancer patients for restoring anti-tumor activities of CD8+ T cells and NK cells, by active specific immunotherapy.

The invention relates to a polypeptide, in particular to a human papilloma virus coat protein L1 short peptide and relative application. The invention is characterized in that the sequence of the human papilloma virus coat protein L1 short peptide is N-EVNLKEKFSADLDQFPLGRKFLLQAGLKAK-C. The invention can simultaneously induce human papilloma virus coat protein L1 short peptide with immunity reaction on high risk type and low risk type, which can induce and form the antibody for various human papilloma virus (HPV) and coat protein (HPV L1), to check various HPV or HPV L1, while the antibody can be used in biological pharmaceutical engineering, to purify and prepare various HPV or HPV L1.

The invention discloses an optical waveguide immunosensor and a detection method thereof. The optical waveguide immunosensor basically comprises an optical waveguide resonator cavity, a magnetic needle and an immunologic reaction tank. The method comprises the following steps of: carrying out surface specificity modification to nano magnetic particles; capturing a substance to be detected by utilizing an antibody-antigen reaction; orderly limiting the nano magnetic particles on the surface of the circular or disc-shaped optical waveguide resonator cavity by utilizing the magnetic needle; sensing refraction index change before and after an immunologic reaction by utilizing an evanescent field; and analyzing corresponding resonance spectrum change to acquire the content of the substance to be detected in a sample. The optical waveguide immunosensor has simple structure. Based on the circular or disc-shaped optical waveguide resonator cavity with compact structure, the nano particles after immunologic specificity modification are absorbed to the optical waveguide surface by the magnetic needle to measure the offset of a resonance frequency and accurately and sensitively detect the immunologic reaction, and the device can be repeatedly used so that the invention has favorable application prospects.

Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.

An object of the present invention is to prepare an antibody that targets CAPRIN-1 specifically expressed on the surface of cancer cells and is superior in antitumor activity to conventional antibodies and to provide use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides use of an antibody targeting an identified cancer antigenic protein specifically expressed on the surface of cancer cells as a therapeutic and/or preventive agent for cancer, specifically, a pharmaceutical composition for treatment and/or prevention of cancer, comprising as an active ingredient an antibody or a fragment thereof which has immunological reactivity with a CAPRIN-1 protein, the antibody or the fragment thereof comprising a heavy chain variable region comprising amino acid sequences represented by SEQ ID NOs: 5, 6, and 7 and a light chain variable region comprising amino acid sequences represented by SEQ ID NOs: 9, 10, and 11.

The present invention discloses a reagent box for detecting nature of third type hepatitis virus antibody by using chemiluminescence method which includes an immunoreaction titration micropore plate and a detecting reagent, the immunoreaction titration micropore plate is a non-transparent polystyrol micropore plate; the detecting reagent includes third type hepatitis viruse antigen, enzyme label antihuman IgG, irradiancy substrates A liquor and irradiancy substrates B liquor. The reagent box uses chemiluminescence immune analysis method for detecting third type hepatitis virus antibody, the irradiancy substrate reacts chemically and releases mass energy by using enzyme catalysis irradiancy substrates for generating an excitation state intermediate body. When the excitation state intermediate body returns to a stable basic state, the excitation state intermediate body can transmit light quantum, utilize an irradiancy signal measurement instrumentation for measuring light quantum yield, the light quantum yield has a direct proportion with a waited-measured substance amount in sample. The method has high sensitivity, high precision and wide linear range; the reagent box has low manufacturing cost which can reduce patient burden and satisfy clinical requirement.

The invention provides an oncolytic virus construction body, an oncolytic virus and application thereof. The oncolytic virus construction body comprises a first nucleic acid molecule and a second nucleic acid molecule, wherein the first nucleic acid molecule encodes a secreted fusion protein molecule; the secreted fusion protein molecule is used for inhibiting immune checkpoints; and the second nucleic acid molecule encodes an immunostimulant molecule. According to the embodiment of the invention, the construction body encodes fusion protein and immunostimulant molecules for inhibiting the immune checkpoints and can inhibit immunosuppression mechanism mediated by the immune checkpoints and immunoreactions which causes individual tumor specificity so as to realize generalized and effectivetumor cell killing.

The invention relates to a preparation and detection method for an ELISA kit detecting Fumonisins. The ELISA kit has the characteristics of sensitive, accurate and fast detection, simple operation and strong specificity, and is suitable for detection of a large number of samples. The kit includes: a Fumonisins antigen coated enzyme label plate, a Fumonisins standard substance, a Fumonisins antibody working solution, a Fumonisins enzyme labeled secondary antibody working solution, a substrate solution A, a substrate solution B, a terminating solution, a concentrated sample dilution solution and a concentrated washing solution. The principle of the Fumonisins detection kit is solid-phase indirect competitive enzyme-linked immunosorbent assay reaction. The extracted sample, the enzyme labeled secondary antibody working solution, and the antibody working solution are added into corresponding enzyme labeled holes, after incubation for a period of time, the substrate solution A and the substrate solution B are added into a washing plate, and under the action of enzyme, the holes can present a blue color. Then the terminating solution is added, and the color changes to yellow from blue. The color depth and the content of Fumonisins in the standard substance or the sample are in an inverse proportion relationship. This method can be directly used for detecting Fumonisins in maize.

The invention provides a manganese dioxide nanometer material. The manganese dioxide nanometer material comprises manganese dioxide nanoparticles and carried matter, wherein the carried matter is compounded onto the surface of the manganese dioxide nanoparticle; the carried matter comprises oligonucleotide CpG and/or antigen; the antigen comprises protein antigen and/or polypeptide antigen. The provided manganese dioxide nanometer material has the advantages that the immunostimulation function of an immunologic adjuvant CpG is greatly improved, the immunity protection function of vaccine is improved, and the inherent defect of effective improving of immune reaction by a large amount of CpG because the oligonucleotide CpG is used as an immunologic stimulant and cannot easily enter the body lymph glands is solved; the manganese dioxide nanometer material is used as a vaccine adjuvant, and can carry the antigen, especially the protein antigen, so that the intake on the antigen by the immune cells in the lymph glands is effectively improved, and the immunogenicity of the antigen is improved; the nanometer adjuvant can be biologically degraded, and can be gradually degraded into manganese ions (Mn<2+>) under the weak acid environment, such as lysosome, and the manganese ions are finally discharged out of the human body.

The present invention relates to viral particles as immunogens against enterovirus infection and a method of producing the same. Specifically, the present invention features that human embryo kidney 293 (HEK 293) cells are used to produce viral particles of Enterovirus A, particularly Coxsackievirus A6 (CVA6) particles or Coxsackievirus A10 (CVA10) particles or both and optionally additional viral particles of other Enterovirus A e.g. Coxsackievirus A16 (CVA16) and/or Enterovirus A71 (EV71). The yield of the viral particles in HEK 293 cells is unexpectedly high and effective to induce an immune response against enterovirus infection, especially CVA6 and CVA10. The present invention also relates to an immunogenic composition against enterovirus infection for human use comprising the viral particles as described herein and a method of preventing enterovirus infection or a disease as caused, particularly Hand-Foot-Mouth diseases (HFMD), by administering the immunogenic composition to a subject in need thereof.

The invention discloses a magnetic bead preparing method and application, and belongs to the technical field of magnetic material preparing. The preparing method comprises the steps that firstly, magnetic nanoparticles with the surface functionalization are prepared, then, at least two magnetic nanoparticles with the surface functionalization are connected through a cross-linking agent, and a magnetic bead with the magnetic content of 70 %-98 % is prepared. The problems that the magnetic content of an existing magnetic bead is low, to achieve fast separation, the size of the magnetic bead is greatly increased, and consequently the suspension stability is reduced are solved. In addition, for the captured component biological reaction, particularly for the immunoreaction, the steric hindrance caused by the small magnetic bead is obviously reduced, the capturing capability and the analyzing and detecting sensitivity are improved, the magnetic bead can be better applied to the biological medicine separation and analysis, and the magnetic bead is particularly suitable for separation of cells, bacteria, viruses, DNA/RNA, protein and the like in biological body fluid or reaction fluid and the clinical biochemistry fast automatic detection based on chemiluminiscence electrochemical luminescence and fluorescence.

The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.

A highly reliable reaction container capable of restraining an initial detection failure (bubble attachment), and a biochemical and/or immunological automatic analyzer loaded with the reaction container. In a reaction container made of a synthetic resin and used for receiving a biological sample and a reagent, developing a biochemical and/or immunological reaction between the biological sample and the reagent, and measuring proceedings of the reaction and/or the state at a predetermined point in time by optical means, an inner wall surface of the reaction container in contact with the biological sample, the reagent, and a reaction product of the biological sample and the reagent has a critical surface tension of not smaller than 25.0 mN/m, or a contact angle between the inner wall surface of the reaction container and a solvent of a reaction solution is not larger than 60 degrees.

The present invention relates to human papillomavirus type bivalent virus-like particle mixture, and human papillomavirus type bivalent virus-like particle mixing protein antigen and its construction method. The present invention includes one kind of cervical carcinoma virus HPV16 L1 antigen and one kind of condyloma acuminata virus HPV11 L1 antigen. The HPV11 L1 gene is first cloned from condyloma acuminata tissue through molecular geological method, and both HPV16 L1 gene cloned from cervical carcinoma tissue and the HPV11 L1 gene are then expressed in the insect cell expression system of baculovirus, so as to constitute recombinant virus strain Bacmid/HPV16-HPV11L1. Animal immunizing test shows that the constituted recombinant protein has excellent immunogenicity and immunoreactivity, and may be used as candidate antigen of gene engineering multivalent vaccine for preventing condyloma acuminata and cervical carcinoma.

The invention discloses a method for detecting microcystin-LR by self-assembly based on the end face of a gold nano-rod, belonging to the technical field of chemical immunoassay. In the invention, the end face of the gold nano-rod is respectively coupled with microcystin coating antigen and anti-microcystin antibody to form a probe of the gold nano-rod; and the synthesized probe of the gold nano-rod performs immunological reaction with the microcystin-LR so as to achieve the detection of the microcystin-LR through the change of the grain diameter of a nano-chain which is formed by the antigen antibody reaction of the end face of the gold nano-rod. The invention performs reaction in a liquid environment, only one step of reaction is needed without washing step, which simplifies the condition of the reaction, reduces labour intensity and improves the detection sensitivity.

The invention discloses a recombinant serine protease inhibitor, a fungus expression vector and a fungus insecticide of recombinant protein. The invention relates to the recombinant serine protease inhibitor; a molecular biology technology is used to construct a recombinant nucleotide sequence; and the recombinant serine protease inhibitor comprises a signal peptide sequence of encoded coccidio beauveriabassiana chitinase and a serine protease inhibitor gene of encoded drosophila, and has a nucleotide sequence shown as SEQ ID NO. 1 and an amino acid sequence shown as SEQ ID NO. 2. The obtained recombinant serine protease inhibitor can inhibit immunoreaction of insects, increase multiplication speed of fungi in haemocoeles, and therefore improve characteristics of insecticide fungus toxicity.